We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulsed Dye Laser for the Psoriatic Nail

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01303185
First Posted: February 24, 2011
Last Update Posted: December 12, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ying-Yi Chiang, Taipei Medical University WanFang Hospital
February 22, 2011
February 24, 2011
December 12, 2014
January 2011
February 2012   (Final data collection date for primary outcome measure)
  • NAPSI [ Time Frame: 3rd and 6th months ]
  • global physician assessment [ Time Frame: 3rd and 6th months ]
Not Provided
Complete list of historical versions of study NCT01303185 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulsed Dye Laser for the Psoriatic Nail
Pulsed Dye Laser for the Psoriatic Nail
The treatment options for nail psoriasis have been limited, and the management of nail psoriasis has been challenging for physicians.To evaluate the effect of pulsed dye laser (PDL) in the treatment of nail psoriasis.
Psoriatic nails of patient's right hand were treated using PDL (595 nm) .The pulsed duration is 1.5ms, the beam diameter is 7mm, and the laser energy is 8.0 to 10.0 J/cm2. The treatment course of pulse dye laser is once monthly for 6 months. Psoriatic nails of both hands are treated with Tazarotene cream for 6 months. Clinical efficacy is statistically evaluated according to Nail Psoriasis Severity Index (NAPSI) score differences between right and left hand one month after 3rd and 6th therapy.
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Psoriatic nail patients
Psoriatic Nail
Not Provided
  • Experimental Group
  • Control Group
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Psoriatic nail refractory to other topical and systemic treatment therapy
  • ≧ 16 years old

Exclusion Criteria:

  • Patient with pregnancy
  • Patient with photo sensitivity
  • Patient with severe wound around finger nails or paronychia
  • Patient with hypersensitivity to Tazarotene cream
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT01303185
99074
No
Not Provided
Not Provided
Ying-Yi Chiang, Taipei Medical University WanFang Hospital
Taipei Medical University WanFang Hospital
Not Provided
Principal Investigator: Ying-Yi Chiang Taipei Medical University WanFang Hospital
Taipei Medical University WanFang Hospital
December 2014